Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Telix-CancerData

More Like This

PR Newswire associated0

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

PR Newswire associated0

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

PR Newswire associated0

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

PR Newswire associated0

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

PR Newswire associated0

Illuccix® Approved in the United Kingdom

PR Newswire associated0

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

PR Newswire associated0

Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS

PR Newswire associated0

Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer